Leniolisib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Leniolisib. Educational only — not medical advice.
Labeled uses
JOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
Source: FDA labeling via NIH DailyMed (set eefbcef8…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.